Calfee C, Liu K, Asare A, Beitler J, Berger P, Coleman M, Crippa A, Discacciati A, Eklund M, Files D, Gandotra S, Gibbs K, Henderson P, Levitt J, Lu R, Matthay M, Meyer N, Russell D, Thomas K, Esserman L, Mittel A, Dzierba A, Madahar P, Serra A, Rosen A, Garcia I, Muir J, Schicchi J, Darmanian A, Wahab R, Gosek K, Auld S, Adelman M, Nugent K, Harris G, Creel-Bulos C, Yang P, Detelich J, Spainhour C, Cobb N, Sonti R, Orr L, Robinson P, Sarafian F, Martinez E, Jones P, Nguyen J, Obermiller T, Weiler-Lisowski B, Kufa L, Saba P, Wyatt J, Youssef F, Tanios M, Blevins D, Macias L, Suarez A, Reyes M, Jung M, Melendrez M, Rosario-Remigio L, Su H, Friedman E, Angelucci C, Chaparro-Rojas F, Sternlieb M, Sutter J, Whealon S, Nair R, Lopez B, Amosu O, Tzehaie H, Wunderink R, Patel C, Simonson A, Dodin J, Oliver T, Lupu R, Meyers M, Albertson T, Haczku A, Hardy E, Morrissey B, Juarez M, Pearson S, Lee R, Amin A, Jauregui A, Fields S, Ng D, Daniel B, Yee K, Jones C, Burnham E, McKeehan J, Ittner C, Reilly J, Mangalmurti N, Rodrigues L, Weisman A, Khan K, Wong S, Yen A, Peterfreund G, Kumar S, Marshall P, Huerta L, Lindgren B, Lee J, Barker A, Lang J, LaRose M, Landreth L, Parks L, Barot H, Koff J, Kazianis J, Boerger L. Clinical trial design during and beyond the pandemic: the I-SPY COVID trial. Nature Medicine 2022, 28: 9-11. PMID: 35058620, PMCID: PMC8922451, DOI: 10.1038/s41591-021-01617-x.Peer-Reviewed Original Research